Goldman Sachs analyst Isaac Ro upgraded Varian Medical Systems to Buy and raised his price target for the shares to $129 from $107. The company’s guidance looks conservative given the new China quota, Ro tells investors in a research note. The new, larger quota in China has the ability to grant approximately 1,400 licenses by 2020, about a 50% increase on a per annum basis from the prior quota, says the analyst. He calls Varian an “out of consensus Buy idea” with China driving upside over the next two years.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.